Souhaitez-vous accéder aux communiqués récents ?

NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

NeOnc’s (NASDAQ: NTHI) recent Abu Dhabi IND authorization for NEO212 highlights an increasingly attractive pharmaceutical industry development strategy

Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease...

Silver Spring, MD, June 18, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today approved the first generic of Xofluza (baloxavir marboxil) tablets, the first single-dose treatment...

~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~ ~ Company intends to submit the BLA in third quarter...

Silver Spring, MD, June 16, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) today approved another over-the-counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram...

NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development

60 Degrees Pharma licensed FSU technology for Australian Chestnut Extract production and plans FDA discussions before refiling its NDIN.

Silver Spring, Md., June 09, 2026 (GLOBE NEWSWIRE) -- Today, the U.S. Food and Drug Administration added bemotrizinol to the list of permitted sunscreen active ingredients, marking a significant...

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing...